⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132258 | 0.85 | LMNA (0.39) | — | |
| SCHEMBL312626 | 0.76 | — | — | |
| SCHEMBL932747 | 0.74 | — | — | |
| SCHEMBL21801438 | 0.74 | PDE10A (0.30) | — | |
| SCHEMBL8029519 | 0.70 | — | — | |
| SCHEMBL19212213 | 0.70 | HSD17B10 (0.37) | — | |
| SCHEMBL732707 | 0.69 | MEN1 (0.53) | — | |
| SCHEMBL9720448 | 0.67 | ALDH1A1 (0.34) | — | |
| SCHEMBL733296 | 0.66 | NPC1 (0.47) | — | |
| SCHEMBL791013 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | claimed |
| CN-116888119-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | claimed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | claimed |
| CN-112384515-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2021-02-19 | — | — | CN | claimed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | claimed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-4396163-A1 | HERBICIDAL MALONAMIDES CONTAINING MONOCYCLIC HETEROAROMATIC RINGS | BASF SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-117903140-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117881662-A | Herbicide malonamide containing monocyclic heteroaromatic ring | 巴斯夫欧洲公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| CN-116888119-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | disclosed |
| CN-112384515-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3759112-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |